High throughput analysis in HER2 positive locally advanced breast cancer: pCR and mutational status

被引：0
|
作者：
Paris, Ida
Minucci, Angelo
Generali, Daniele
Nanni, Simona
D'angelo, Tatiana
Pavese, Francesco
Fabi, Alessandra
De Bonis, Maria
Cannita, Katia
Piermattei, Alessia
Tiberi, Giordana
Fuso, Paola
Carbognin, Luisa
Rotondaro, Silvia
Nero, Camilla
Giacomini, Flavia
Pasciuto, Tina
Marrazzo, Maria
Giaco, Luciano
Mule, Antonino
Masetti, Riccardo
Franceschini, Gianluca
Garganese, Giorgia
Giannarelli, Diana
Scambia, Giovanni
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO4-01-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO4-01-02
引用
收藏
页数：3
相关论文
共 50 条
  • [31] High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth
    Leivonen, Suvi-Katri
    Sahlberg, Kristine Kleivi
    Makela, Rami
    Due, Eldri Undlien
    Kallioniemi, Olli
    Borresen-Dale, Anne-Lise
    Perala, Merja
    MOLECULAR ONCOLOGY, 2014, 8 (01) : 93 - 104
  • [32] Methodology Used to Determine HER2 Status Correlates with Response to Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer
    Cheng, Esther
    McIntire, Patrick
    D'Alfonso, Timothy
    Ginter, Paula
    LABORATORY INVESTIGATION, 2018, 98 : 54 - 54
  • [33] Brain metastasis in advanced breast cancer: high risk in HER2 positive but not in triple negative patients
    Wagner, B. D.
    Langkjer, S. T.
    EJC SUPPLEMENTS, 2009, 7 (02): : 290 - 290
  • [34] Prognostic significance of HER2 loss after HER2-targeted neoadjuvant treatment in patients with HER2-positive locally advanced breast cancer
    Kutlu, Yasin
    Cekin, Ruhper
    Aydin, Sabin Goktas
    Shbair, Abdallah T. M.
    Bilici, Ahmet
    Arici, Serdar
    Oven, Bala Basak
    Acikgoz, Ozgur
    Ozcan, Erkan
    Olmez, Omer Fatih
    Cakir, Asli
    Seker, Mesut
    CURRENT PROBLEMS IN CANCER, 2024, 50
  • [35] Quantitative PCR and HER2 testing in breast cancer
    Barberis, Massimo
    Pellegrini, Caterina
    Cannone, Maria
    Arizzi, Carmelo
    Coggi, Guido
    Bosari, Silvano
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2008, 129 (04) : 563 - 570
  • [36] The Efficacy of Neoadjuvant Chemotherapy for HER-2-Positive Locally Advanced Breast Cancer and Survival Analysis
    Zhang, Wei
    Tian, Huan
    Yang, Shi-hong
    ANALYTICAL CELLULAR PATHOLOGY, 2017, 2017
  • [37] Analysis of biomarkers in a pilot study of pertuzumab, trastuzumab and eribulin for advanced HER2 positive breast cancer
    Tono, Yasutaka
    Ishihara, Mikiya
    Miyahara, Yoshihiro
    Ikeda, Hiroaki
    Shiku, Hiroshi
    Shiraishi, Taizo
    Mizuno, Toshiro
    Katayama, Naoyuki
    ANNALS OF ONCOLOGY, 2016, 27
  • [38] Delayed breast cancer surgery in HER2 positive breast cancer
    Hur, Ho
    Le, Amy
    Chang, Helena R.
    CANCER RESEARCH, 2020, 80 (04)
  • [39] HER-2 positive locally advanced breast cancer: one or two entities?
    Rahal, M.
    Abdelwarith, A.
    Hassen, E.
    Deo, S.
    Ramadan, H.
    Al Naimy, N.
    Al Eissa, N.
    Al Garni, A.
    Al Idrissi, M.
    Al Faraj, A.
    EJC SUPPLEMENTS, 2009, 7 (02): : 286 - 286
  • [40] How We Treat Locally Advanced HER2-Positive Breast Cancer
    Exman, Pedro
    Pernas, Sonia
    Tolaney, Sara M.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (05) : 271 - 280
12345